Valdecoxib (BioDeep_00000001946)

 

Secondary id: BioDeep_00000399170

human metabolite Endogenous Chemicals and Drugs


代谢物信息卡片


4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide

化学式: C16H14N2O3S (314.07250940000006)
中文名称: 伐地考昔
谱图信息: 最多检出来源 Escherichia coli(natural_products) 94.44%

分子结构信息

SMILES: CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
InChI: InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)

描述信息

Valdecoxib is a prescription drug used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug, or NSAID, and should not be taken by anyone allergic to these types of medications. [HMDB]
Valdecoxib is a prescription drug used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug, or NSAID, and should not be taken by anyone allergic to these types of medications.
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AH - Coxibs
D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors
D004791 - Enzyme Inhibitors > D016861 - Cyclooxygenase Inhibitors > D052246 - Cyclooxygenase 2 Inhibitors
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
D000893 - Anti-Inflammatory Agents

同义名列表

13 个代谢物同义名

4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide; 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulphonamide; p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulphonamide; 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Pfizer brand OF valdecoxib; Valdecoxibum; Valdecoxib; Valecoxib; Bextra; Valdyn; Kudeq; COX



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Seung Yeon Park, Wonjun Cho, A M Abd El-Aty, Ahmet Hacimuftuoglu, Ji Hoon Jeong, Tae Woo Jung. Valdecoxib attenuates lipid-induced hepatic steatosis through autophagy-mediated suppression of endoplasmic reticulum stress. Biochemical pharmacology. 2022 05; 199(?):115022. doi: 10.1016/j.bcp.2022.115022. [PMID: 35358477]
  • Tae Jin Kim, Hyun Jung Lee, Do Hyeon Pyun, A M Abd El-Aty, Ji Hoon Jeong, Tae Woo Jung. Valdecoxib improves lipid-induced skeletal muscle insulin resistance via simultaneous suppression of inflammation and endoplasmic reticulum stress. Biochemical pharmacology. 2021 06; 188(?):114557. doi: 10.1016/j.bcp.2021.114557. [PMID: 33844985]
  • Mengchun Chen, Wei Sun, Zhe Wang, Chengke Huang, Guoxin Hu, Yijie Chen, Ledan Wang. Determination of parecoxib and valdecoxib in rat plasma by UPLC-MS/MS and its application to pharmacokinetics studies. BMC pharmacology & toxicology. 2020 04; 21(1):27. doi: 10.1186/s40360-020-00406-5. [PMID: 32264977]
  • Shuang-Long Li, Yong-Liang Zhu, Chun-Yang Zhu, Shao-Bin Li, Zi-Heng Li, Xiang-Jun Qiu. Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. Drug design, development and therapy. 2020; 14(?):1117-1125. doi: 10.2147/dddt.s226349. [PMID: 32214797]
  • Jie Hu, Bing-Feng Lv, Wen-Jing Guo, Bo-Wen Wang, Di Miao, Xiang-Jun Qiu, Xing-Peng Chen. Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. BioMed research international. 2020; 2020(?):1563874. doi: 10.1155/2020/1563874. [PMID: 32832543]
  • Xiaoliang Jin, Fang Zhou, Yan Liu, Chen Cheng, Lan Yao, Yuanwei Jia, Guangji Wang, Jingwei Zhang. Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice. Journal of pharmaceutical and biomedical analysis. 2018 Sep; 158(?):1-7. doi: 10.1016/j.jpba.2018.05.034. [PMID: 29843006]
  • Jaya Prabhakaran, Mark Underwood, Francesca Zanderigo, Norman R Simpson, Anna R Cooper, Jeffrey Matthew, Harry Rubin-Falcone, Ramin V Parsey, J John Mann, J S Dileep Kumar. Radiosynthesis and in vivo evaluation of [11C]MOV as a PET imaging agent for COX-2. Bioorganic & medicinal chemistry letters. 2018 08; 28(14):2432-2435. doi: 10.1016/j.bmcl.2018.06.015. [PMID: 29929881]
  • Aysun Inan Genç, Seher Gok, Sreeparna Banerjee, Feride Severcan. Valdecoxib Recovers the Lipid Composition, Order and Dynamics in Colon Cancer Cell Lines Independent of COX-2 Expression: An ATR-FTIR Spectroscopy Study. Applied spectroscopy. 2017 01; 71(1):105-117. doi: 10.1177/0003702816654164. [PMID: 27354402]
  • Meina Liu, Qiuyang Yu, Ping Li, Meng Zhu, Mingming Fang, Bingjun Sun, Mengchi Sun, Yinghua Sun, Peng Zhang, Zhonggui He, Jin Sun, Yongjun Wang, Xiaohong Liu. Simultaneous determination of parecoxib sodium and its active metabolite valdecoxib in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after intravenous and intramuscular administration. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2016 Jun; 1022(?):220-229. doi: 10.1016/j.jchromb.2016.04.009. [PMID: 27107851]
  • T W Kim, C Vercelli, A Briganti, G Re, M Giorgi. The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats. Veterinary journal (London, England : 1997). 2014 Oct; 202(1):37-42. doi: 10.1016/j.tvjl.2014.07.025. [PMID: 25135338]
  • Daphna Laifenfeld, Luping Qiu, Rachel Swiss, Jennifer Park, Michael Macoritto, Yvonne Will, Husam S Younis, Michael Lawton. Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicological sciences : an official journal of the Society of Toxicology. 2014 Jan; 137(1):234-48. doi: 10.1093/toxsci/kft232. [PMID: 24136188]
  • Maria V Encinas, Eduardo Lissi, Claudio Vergara. Association of valdecoxib, a nonsteroidal anti-inflammatory drug, with human serum albumin. Photochemistry and photobiology. 2013 Nov; 89(6):1399-405. doi: 10.1111/php.12158. [PMID: 23952101]
  • Ghan-Shyam Lohiya, Piyush Lohiya, Vamsi Krishna, Sunita Lohiya. Death related to Ibuprofen, valdecoxib, and medical errors: case report and medicolegal issues. Journal of occupational and environmental medicine. 2013 Jun; 55(6):601-3. doi: 10.1097/jom.0b013e3182972ecf. [PMID: 23743867]
  • Cho-Ming Loi, Dennis A Smith, Deepak Dalvie. Which metabolites circulate?. Drug metabolism and disposition: the biological fate of chemicals. 2013 May; 41(5):933-51. doi: 10.1124/dmd.112.050278. [PMID: 23454828]
  • M Giorgi, G Saccomanni, S Del Carlo, C Manera, E Lavy. Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles. Veterinary journal (London, England : 1997). 2012 Jul; 193(1):246-50. doi: 10.1016/j.tvjl.2011.11.005. [PMID: 22130459]
  • Bruce Hullett, Sam Salman, Sean J O'Halloran, Deborah Peirce, Kylie Davies, Kenneth F Ilett. Development of a population pharmacokinetic model for parecoxib and its active metabolite valdecoxib after parenteral parecoxib administration in children. Anesthesiology. 2012 May; 116(5):1124-33. doi: 10.1097/aln.0b013e31825154ef. [PMID: 22450476]
  • Michael J Paech, Sam Salman, Kenneth F Ilett, Sean J O'Halloran, Neil A Muchatuta. Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery: a comparison of naive pooled data analysis and nonlinear mixed-effects modeling. Anesthesia and analgesia. 2012 Apr; 114(4):837-44. doi: 10.1213/ane.0b013e3182468fa7. [PMID: 22344242]
  • Andy J Liedtke, Brenda C Crews, Cristina M Daniel, Anna L Blobaum, Philip J Kingsley, Kebreab Ghebreselasie, Lawrence J Marnett. Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold. Journal of medicinal chemistry. 2012 Mar; 55(5):2287-300. doi: 10.1021/jm201528b. [PMID: 22263894]
  • G Saccomanni, M Giorgi, S Del Carlo, C Manera, A Saba, M Macchia. Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. Analytical and bioanalytical chemistry. 2011 Sep; 401(5):1677-84. doi: 10.1007/s00216-011-5244-4. [PMID: 21769548]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • Anke Olliges, Stefanie Wimmer, Rolf M Nüsing. Defects in mouse nephrogenesis induced by selective and non-selective cyclooxygenase-2 inhibitors. British journal of pharmacology. 2011 Jul; 163(5):927-36. doi: 10.1111/j.1476-5381.2011.01313.x. [PMID: 21391980]
  • Amit Gupta, Anil Kumar, S K Kulkarni. Targeting oxidative stress, mitochondrial dysfunction and neuroinflammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice. Progress in neuro-psychopharmacology & biological psychiatry. 2011 Jun; 35(4):974-81. doi: 10.1016/j.pnpbp.2011.01.017. [PMID: 21291942]
  • Olav A Christophersen, Anna Haug. Animal products, diseases and drugs: a plea for better integration between agricultural sciences, human nutrition and human pharmacology. Lipids in health and disease. 2011 Jan; 10(?):16. doi: 10.1186/1476-511x-10-16. [PMID: 21247506]
  • Piet Borgdorff, M Louis Handoko, Yeun Ying Wong, Geert Jan Tangelder. COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood. The open cardiovascular medicine journal. 2010 Oct; 4(?):198-205. doi: 10.2174/1874192401004010198. [PMID: 21331307]
  • Metesh Acharya, Joel Dunning. Does the use of non-steroidal anti-inflammatory drugs after cardiac surgery increase the risk of renal failure?. Interactive cardiovascular and thoracic surgery. 2010 Oct; 11(4):461-7. doi: 10.1510/icvts.2010.239053. [PMID: 20639308]
  • Stein Erik Utvåg, Ole Martin Fuskevåg, Hamid Shegarfi, Olav Reikerås. Short-term treatment with COX-2 inhibitors does not impair fracture healing. Journal of investigative surgery : the official journal of the Academy of Surgical Research. 2010 Oct; 23(5):257-61. doi: 10.3109/08941939.2010.481009. [PMID: 20874480]
  • Włodzimierz Matysiak, Barbara Jodłowska-Jedrych. Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies. Protoplasma. 2010 Oct; 246(1-4):109-18. doi: 10.1007/s00709-010-0194-9. [PMID: 20721677]
  • Masahide Hamaguchi, Takahiro Seno, Aihiro Yamamoto, Masataka Kohno, Masatoshi Kadoya, Hidetaka Ishino, Eishi Ashihara, Shinya Kimura, Yoshinori Tsubakimoto, Hiroki Takata, Toshikazu Yoshikawa, Taira Maekawa, Yutaka Kawahito. Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation. Journal of clinical biochemistry and nutrition. 2010 Sep; 47(2):138-47. doi: 10.3164/jcbn.10-33. [PMID: 20838569]
  • Shepherd R Singer, Michal Amit-Kohn, Samuel Weiss, Jonathan Rosenblum, Guy Maoz, Noah Samuels, Esther Lukasiewicz, Laurence Freedman, Ora Paltiel, Menachem Itzchaki, Meir Niska, Menachem Oberbaum. Traumeel S for pain relief following hallux valgus surgery: a randomized controlled trial. BMC clinical pharmacology. 2010 Apr; 10(?):9. doi: 10.1186/1472-6904-10-9. [PMID: 20380750]
  • Thomas J Montine, Joshua A Sonnen, Ginger Milne, Laura D Baker, John C S Breitner. Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. PloS one. 2010 Feb; 5(2):e9340. doi: 10.1371/journal.pone.0009340. [PMID: 20174466]
  • Anil Kumar, Beenta Kumari, Puneet Kumar. Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress. Neuroscience bulletin. 2010 Feb; 26(1):17-27. doi: 10.1007/s12264-010-0713-x. [PMID: 20101269]
  • Bertold Renner, Josef Zacher, Asokumar Buvanendran, Gerrit Walter, Jochen Strauss, Kay Brune. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study. Naunyn-Schmiedeberg's archives of pharmacology. 2010 Feb; 381(2):127-36. doi: 10.1007/s00210-009-0482-0. [PMID: 20052461]
  • Said A Said, Abd el-Galil E Amr, Nermien M Sabry, Mohamed M Abdalla. Analgesic, anticonvulsant and anti-inflammatory activities of some synthesized benzodiazipine, triazolopyrimidine and bis-imide derivatives. European journal of medicinal chemistry. 2009 Dec; 44(12):4787-92. doi: 10.1016/j.ejmech.2009.07.013. [PMID: 19682771]
  • Thorsten J Maier, Susanne Schiffmann, Ivonne Wobst, Kerstin Birod, Carlo Angioni, Marika Hoffmann, Jakob J Lopez, Clemens Glaubitz, Dieter Steinhilber, Gerd Geisslinger, Sabine Grösch. Cellular membranes function as a storage compartment for celecoxib. Journal of molecular medicine (Berlin, Germany). 2009 Oct; 87(10):981-93. doi: 10.1007/s00109-009-0506-8. [PMID: 19641861]
  • Sagar M Agnihotri, Pradeep R Vavia. Pharmacokinetics of intramuscular microparticle depot of valdecoxib in an experimental model. Drug development and industrial pharmacy. 2009 Sep; 35(9):1043-7. doi: 10.1080/03639040902762979. [PMID: 19365783]
  • Muzamil Ahmad, Yuquin Zhang, Hao Liu, Marie E Rose, Steven H Graham. Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. Brain research. 2009 Jul; 1279(?):168-73. doi: 10.1016/j.brainres.2009.05.020. [PMID: 19446533]
  • Mika Hilvo, Anna Maria Salzano, Alessio Innocenti, Markku S Kulomaa, Andrea Scozzafava, Andrea Scaloni, Seppo Parkkila, Claudiu T Supuran. Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. Journal of medicinal chemistry. 2009 Feb; 52(3):646-54. doi: 10.1021/jm801267c. [PMID: 19193158]
  • Joy L Frestedt, Michael A Kuskowski, John L Zenk. A natural seaweed derived mineral supplement (Aquamin F) for knee osteoarthritis: a randomised, placebo controlled pilot study. Nutrition journal. 2009 Feb; 8(?):7. doi: 10.1186/1475-2891-8-7. [PMID: 19187557]
  • Neelam Seedher, Sonu Bhatia. Competition between COX-2 inhibitors and some other drugs for binding sites on human serum albumin. Drug metabolism and drug interactions. 2009; 24(1):37-56. doi: 10.1515/dmdi.2009.24.1.37. [PMID: 19354000]
  • Neelam Seedher, Sonu Bhatia. Complexation of cox-2 inhibitors with bovine serum albumin: interaction mechanism. Pharmaceutical development and technology. 2009; 14(4):343-9. doi: 10.1080/10837450802647292. [PMID: 19235548]
  • E Ernst. Frankincense: systematic review. BMJ (Clinical research ed.). 2008 Dec; 337(?):a2813. doi: 10.1136/bmj.a2813. [PMID: 19091760]
  • V Chaignat, H Danuser, M H Stoffel, S Z'brun, U E Studer, M Mevissen. Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo. British journal of pharmacology. 2008 Jul; 154(6):1297-307. doi: 10.1038/bjp.2008.193. [PMID: 18500363]
  • D Vijaya Bharathi, A Naidu, B Jagadeesh, K N K Maha Laxmi, P Revathi Naga Laxmi, Pandu Ranga Reddy, Ramesh Mullangi. Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study. Biomedical chromatography : BMC. 2008 Jun; 22(6):645-53. doi: 10.1002/bmc.983. [PMID: 18254142]
  • K G Kowalski, S Olson, A E Remmers, M M Hutmacher. Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. Clinical pharmacology and therapeutics. 2008 Jun; 83(6):857-66. doi: 10.1038/sj.clpt.6100374. [PMID: 17882158]
  • Jean C Rousseau, Eren U Sumer, Gert Hein, Bodil C Sondergaard, Suzi H Madsen, Christian Pedersen, Thomas Neumann, Andreas Mueller, Per Qvist, Pierre Delmas, Morten A Karsdal. Patients with rheumatoid arthritis have an altered circulatory aggrecan profile. BMC musculoskeletal disorders. 2008 May; 9(?):74. doi: 10.1186/1471-2474-9-74. [PMID: 18507823]
  • Wei Li, Yan Liu, Muhammad Mahmood Mukhtar, Rui Gong, Ying Pan, Sahibzada T Rasool, Yecheng Gao, Lei Kang, Qian Hao, Guiqing Peng, Yanni Chen, Xin Chen, Jianguo Wu, Ying Zhu. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PloS one. 2008 Apr; 3(4):e1985. doi: 10.1371/journal.pone.0001985. [PMID: 18414668]
  • V Mehta, A Johnston, R Cheung, A Bello, R M Langford. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clinical pharmacology and therapeutics. 2008 Mar; 83(3):430-5. doi: 10.1038/sj.clpt.6100304. [PMID: 17687276]
  • V Molmoori, K Srisailam, V Ciddi. Biotransformation of valdecoxib by plant cell cultures. Applied biochemistry and biotechnology. 2008 Mar; 144(3):201-12. doi: 10.1007/s12010-007-8102-2. [PMID: 18556810]
  • Joy L Frestedt, Melanie Walsh, Michael A Kuskowski, John L Zenk. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. Nutrition journal. 2008 Feb; 7(?):9. doi: 10.1186/1475-2891-7-9. [PMID: 18279523]
  • Dingzhi Wang, Raymond N Dubois. Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR research. 2008; 2008(?):931074. doi: 10.1155/2008/931074. [PMID: 18551185]
  • William J Welch, Kinjal Patel, Paul Modlinger, Margarida Mendonca, Noritaka Kawada, Kathryn Dennehy, Shakil Aslam, Christopher S Wilcox. Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension. American journal of physiology. Heart and circulatory physiology. 2007 Nov; 293(5):H2644-9. doi: 10.1152/ajpheart.00748.2007. [PMID: 17766473]
  • Beenta Kumari, Anil Kumar, Ashish Dhir. Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations. Pharmacological reports : PR. 2007 Nov; 59(6):699-707. doi: . [PMID: 18195459]
  • Gabriella Coruzzi, Nicola Venturi, Silvana Spaggiari. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta bio-medica : Atenei Parmensis. 2007 Aug; 78(2):96-110. doi: . [PMID: 17933277]
  • C X X Guo, M G Irwin, K M C Cheung, D Chan. An effective dose of valdecoxib in experimental mouse models of pain. Methods and findings in experimental and clinical pharmacology. 2007 Jul; 29(6):383-8. doi: 10.1358/mf.2007.29.6.1119170. [PMID: 17922065]
  • K S Kesavanarayanan, Mohanavelu Nappinnai, Raju Ilavarasan. Topical dosage form of valdecoxib: preparation and pharmacological evaluation. Acta pharmaceutica (Zagreb, Croatia). 2007 Jun; 57(2):199-209. doi: 10.2478/v10007-007-0016-6. [PMID: 17507316]
  • P Kumar, S S V Padi, P S Naidu, A Kumar. Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundamental & clinical pharmacology. 2007 Jun; 21(3):297-306. doi: 10.1111/j.1472-8206.2007.00485.x. [PMID: 17521299]
  • Marta L Capone, Stefania Tacconelli, Luigia Di Francesco, Andrea Sacchetti, Maria G Sciulli, Paola Patrignani. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins & other lipid mediators. 2007 Jan; 82(1-4):85-94. doi: 10.1016/j.prostaglandins.2006.05.019. [PMID: 17164136]
  • Edwin S L Chan, Hongwei Zhang, Patricia Fernandez, Sari D Edelman, Michael H Pillinger, Louis Ragolia, Thomas Palaia, Steven Carsons, Allison B Reiss. Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis research & therapy. 2007; 9(1):R4. doi: 10.1186/ar2109. [PMID: 17244362]
  • Anil Kumar, Neha Seghal, Satyanaryana Venketeshwara Padi, Pattipati Sreenivaslu Naidu. Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. European journal of pharmacology. 2006 Dec; 551(1-3):58-66. doi: 10.1016/j.ejphar.2006.08.076. [PMID: 17027965]
  • Félix M Arellano, Marianne Ulcickas Yood, Charles E Wentworth, Susan A Oliveria, Elena Rivero, Anila Verma, Kenneth J Rothman. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiology and drug safety. 2006 Dec; 15(12):861-72. doi: 10.1002/pds.1343. [PMID: 17086563]
  • R Andrew Moore, Sheena Derry, Ceri J Phillips, Henry J McQuay. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC musculoskeletal disorders. 2006 Oct; 7(?):79. doi: 10.1186/1471-2474-7-79. [PMID: 17054784]
  • M Joshi, V Patravale. Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib. Drug development and industrial pharmacy. 2006 Sep; 32(8):911-8. doi: 10.1080/03639040600814676. [PMID: 16954103]
  • Jean-Pierre Valat, Gilbert Deray, François Héloire. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse medicale (Paris, France : 1983). 2006 Sep; 35 Suppl 1(?):25-34. doi: 10.1016/s0755-4982(06)74937-5. [PMID: 17870550]
  • U Werner, C Lamprecht, D Werner, S Schaefer, H Wuttke, B Hinz, M F Fromm, K Brune. Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. International journal of clinical pharmacology and therapeutics. 2006 Sep; 44(9):397-400. doi: 10.5414/cpp44397. [PMID: 16995327]
  • Neelam Seedher, Sonu Bhatia. Reversible binding of celecoxib and valdecoxib with human serum albumin using fluorescence spectroscopic technique. Pharmacological research. 2006 Aug; 54(2):77-84. doi: 10.1016/j.phrs.2006.02.008. [PMID: 16600620]
  • R M Langford, V Mehta. Selective cyclooxygenase inhibition: its role in pain and anaesthesia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2006 Aug; 60(7):323-8. doi: 10.1016/j.biopha.2006.06.017. [PMID: 16837162]
  • Michael Bucher, Frieder K Kees, Barbara Messmann, Dirk Lunz, Stephan Rath, Marek Zelenka, Hans J Schlitt, Jonny Hobbhahn. Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1. European journal of pharmacology. 2006 May; 536(3):296-300. doi: 10.1016/j.ejphar.2006.03.009. [PMID: 16581062]
  • Lawrence Levine. Cyclooxygenase expression is not required for release of arachidonic acid from cells by some nonsteroidal anti-inflammatory drugs and cancer preventive agents. BMC pharmacology. 2006 Mar; 6(?):7. doi: 10.1186/1471-2210-6-7. [PMID: 16571133]
  • S Keshetty, R K Venisetty, V Molmoori, V Ciddi. Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. Die Pharmazie. 2006 Mar; 61(3):245-6. doi: NULL. [PMID: 16599270]
  • Venkata V Pavan Kumar, Menon C A Vinu, Addepalli V Ramani, Ramesh Mullangi, Nuggehally R Srinivas. Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. Biomedical chromatography : BMC. 2006 Jan; 20(1):125-32. doi: 10.1002/bmc.539. [PMID: 16013036]
  • R Preston Mason, Mary F Walter, Hyesun P McNulty, Samuel F Lockwood, Jungsoo Byun, Charles A Day, Robert F Jacob. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. Journal of cardiovascular pharmacology. 2006; 47 Suppl 1(?):S7-14. doi: 10.1097/00005344-200605001-00003. [PMID: 16785833]
  • Elliot V Hersh, Edward T Lally, Paul A Moore. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?. Current medical research and opinion. 2005 Aug; 21(8):1217-26. doi: 10.1185/030079905x56367. [PMID: 16083531]
  • Nenad Sarapa, Margaret R Britto, Michelle B Mainka, Kourosh Parivar. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. European journal of clinical pharmacology. 2005 Jun; 61(4):247-56. doi: 10.1007/s00228-005-0909-6. [PMID: 15887009]
  • R Nageswara Rao, S Meena, D Nagaraju, A Raghu Ram Rao. Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids. Biomedical chromatography : BMC. 2005 Jun; 19(5):362-8. doi: 10.1002/bmc.458. [PMID: 15627281]
  • Bernard Bannwarth, Francis Berenbaum. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. Expert opinion on investigational drugs. 2005 Apr; 14(4):521-33. doi: 10.1517/13543784.14.4.521. [PMID: 15882125]
  • Ulrike Werner, Dierk Werner, Burkhard Hinz, Christoph Lambrecht, Kay Brune. A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. Biomedical chromatography : BMC. 2005 Mar; 19(2):113-8. doi: 10.1002/bmc.423. [PMID: 15473012]
  • A S Mühlfeld, J Floege. COX-2 inhibitor induced anuric renal failure in a previously healthy young woman. Clinical nephrology. 2005 Mar; 63(3):221-4. doi: 10.5414/cnp63221. [PMID: 15786824]
  • Gregory Dembo, Sang B Park, Evan D Kharasch. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology. 2005 Feb; 102(2):409-15. doi: 10.1097/00000542-200502000-00026. [PMID: 15681959]
  • Giuseppe D Norata, Alberico L Catapano. Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vascular health and risk management. 2005; 1(2):119-29. doi: 10.2147/vhrm.1.2.119.64083. [PMID: 17315398]
  • Mary F Walter, Robert F Jacob, Charles A Day, Rachel Dahlborg, Yujia Weng, R Preston Mason. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004 Dec; 177(2):235-43. doi: 10.1016/j.atherosclerosis.2004.10.001. [PMID: 15530895]
  • James F Knudsen, Uno Carlsson, Per Hammarström, Gerald H Sokol, Louis R Cantilena. The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II. Inflammation. 2004 Oct; 28(5):285-90. doi: 10.1007/s10753-004-6052-1. [PMID: 16134002]
  • Jonna M Lehtonen, Seppo Parkkila, Daniela Vullo, Angela Casini, Andrea Scozzafava, Claudiu T Supuran. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design. Bioorganic & medicinal chemistry letters. 2004 Jul; 14(14):3757-62. doi: 10.1016/j.bmcl.2004.04.106. [PMID: 15203157]
  • Timothy D Warner, Jane A Mitchell. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2004 May; 18(7):790-804. doi: 10.1096/fj.03-0645rev. [PMID: 15117884]
  • N V S Ramakrishna, K N Vishwottam, S Wishu, M Koteshwara. Quantitation of Valdecoxib in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection using liquid-liquid extraction. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Apr; 802(2):271-5. doi: 10.1016/j.jchromb.2003.11.039. [PMID: 15018787]
  • Sean P Curtis, Jennifer Ng, Qinfen Yu, Sumiko Shingo, Gina Bergman, Calogera L McCormick, Alise S Reicin. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clinical therapeutics. 2004 Jan; 26(1):70-83. doi: 10.1016/s0149-2918(04)90007-0. [PMID: 14996519]
  • Ji Y Zhang, Douglas M Fast, Alan P Breau. Development and validation of an automated SPE-LC-MS/MS assay for valdecoxib and its hydroxylated metabolite in human plasma. Journal of pharmaceutical and biomedical analysis. 2003 Sep; 33(1):61-72. doi: 10.1016/s0731-7085(03)00349-2. [PMID: 12946532]
  • Philip T Leese, David P Recker, Jeffrey D Kent. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. Journal of clinical pharmacology. 2003 May; 43(5):504-13. doi: 10.1177/0091270003252234. [PMID: 12751271]
  • Andra E Ibrahim, Jennifer Feldman, Aziz Karim, Evan D Kharasch. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003 Apr; 98(4):853-61. doi: 10.1097/00000542-200304000-00011. [PMID: 12657846]
  • Ji Y Zhang, Josh J Yuan, Yue-Fen Wang, Roy H Bible, Alan P Breau. Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. Drug metabolism and disposition: the biological fate of chemicals. 2003 Apr; 31(4):491-501. doi: 10.1124/dmd.31.4.491. [PMID: 12642477]
  • Franciszek Burdan, Agnieszka Korobowicz. [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2003 Apr; 14(82):352-5. doi: NULL. [PMID: 12868201]
  • Ji Y Zhang, Douglas M Fast, Alan P Breau. Determination of valdecoxib and its metabolites in human urine by automated solid-phase extraction-liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Feb; 785(1):123-34. doi: 10.1016/s1570-0232(02)00863-2. [PMID: 12535845]
  • S Alsalameh, M Burian, G Mahr, B G Woodcock, G Geisslinger. Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Alimentary pharmacology & therapeutics. 2003 Feb; 17(4):489-501. doi: 10.1046/j.1365-2036.2003.01460.x. [PMID: 12622757]
  • Andra Ibrahim, Aziz Karim, Jennifer Feldman, Evan Kharasch. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesthesia and analgesia. 2002 Sep; 95(3):667-73, table of contents. doi: 10.1097/00000539-200209000-00032. [PMID: 12198057]
  • Josh J Yuan, Dai-Chang Yang, Ji Y Zhang, Roy Bible, Aziz Karim, John W A Findlay. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug metabolism and disposition: the biological fate of chemicals. 2002 Sep; 30(9):1013-21. doi: 10.1124/dmd.30.9.1013. [PMID: 12167567]
  • Raymond Sinatra. Role of COX-2 inhibitors in the evolution of acute pain management. Journal of pain and symptom management. 2002 Jul; 24(1 Suppl):S18-27. doi: 10.1016/s0885-3924(02)00410-4. [PMID: 12204484]
  • Philip T Leese, Sheela Talwalker, Jeffrey D Kent, David P Recker. Valdecoxib does not impair platelet function. The American journal of emergency medicine. 2002 Jul; 20(4):275-81. doi: 10.1053/ajem.2002.32635. [PMID: 12098171]
  • NULL. Valdecoxib (Bextra)--a new cox-2 inhibitor. The Medical letter on drugs and therapeutics. 2002 Apr; 44(1129):39-40. doi: NULL. [PMID: 11981510]
  • Andra Ibrahim, Sang Park, Jennifer Feldman, Aziz Karim, Evan D Kharasch. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Anesthesiology. 2002 Jan; 96(1):88-95. doi: 10.1097/00000542-200201000-00020. [PMID: 11753007]
  • Stefania Tacconelli, Marta L Capone, Maria G Sciulli, Emanuela Ricciotti, Paola Patrignani. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Current medical research and opinion. 2002; 18(8):503-11. doi: 10.1185/030079902125001335. [PMID: 12564662]